Pregnancy Considerations for Patients With Interstitial Lung Disease

被引:3
|
作者
Grant-Orser, Amanda [1 ]
Metcalfe, Amy [2 ,3 ]
Pope, Janet E. [4 ]
Johannson, Kerri A. [1 ,3 ,5 ]
机构
[1] Univ Calgary, Div Respirol, Dept Med, Calgary, AB, Canada
[2] Univ Calgary, Dept Obstet & Gynecol, Calgary, AB, Canada
[3] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada
[4] Univ Western Ontario, Div Rheumatol, Dept Med, St Josephs Hlth Care, London, ON, Canada
[5] Univ Calgary, Snyder Inst Chron Dis, Calgary, AB, Canada
关键词
interstitial lung disease; outcomes; pregnancy; safety; PULMONARY-FIBROSIS; BREAST-MILK; THORACIC SOCIETY; DOUBLE-BLIND; SAFETY; MYCOPHENOLATE; TOCILIZUMAB; MANAGEMENT; PHYSIOLOGY; EXPOSURE;
D O I
10.1016/j.chest.2022.06.024
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Advances in our understanding of interstitial lung disease (ILD) pathophysiology and natural history have led to the development of guidelines for the diagnosis and management of several of these complex diseases. The demographics of patients with ILD indicate the disease is not restricted to older adults. Connective tissue disease-associated ILD, familial pulmonary fibrosis, and post-COVID-19 fibrosis may affect women of child-bearing age. Recent trials have excluded pregnant women, thereby limiting the applicability of contemporary therapeutic advances to these patients. This review synthesizes the current knowledge of pregnancy outcomes in those with ILD, with a focus on connective tissue disease-associated ILD, and potential treatment implications for patients with ILD who are pregnant or considering pregnancy. Pregnancy considerations for patients with ILD include the need for preconception counseling and planning to ensure disease stability, medication and vaccination optimization, and multidisciplinary involvement of a patient's pulmonologist, obstetrician, and, when indicated, rheumatologist and genetic counselor. Evidence to date suggests that women with ILD can have safe and healthy pregnancies but that complications may occur in those with severe ILD.
引用
收藏
页码:1093 / 1105
页数:13
相关论文
共 50 条
  • [41] Interstitial lung disease in patients with systemic sclerosis: what can we learn from the SENSCIS trial?
    Assassi, S.
    Tumuluri, S.
    Levin, R. W.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (08) : 1713 - 1719
  • [42] Clinical Predictors of Lung-Function Decline in Systemic-Sclerosis-Associated Interstitial Lung Disease Patients with Normal Spirometry
    Nagy, Tamas
    Toth, Nora Melinda
    Palmer, Erik
    Polivka, Lorinc
    Csoma, Balazs
    Nagy, Alexandra
    Eszes, Noemi
    Vincze, Krisztina
    Barczi, Eniko
    Bohacs, Aniko
    Tarnoki, Adam Domonkos
    Tarnoki, David Laszlo
    Nagy, Gyorgy
    Kiss, Emese
    Maurovich-Horvat, Pal
    Muller, Veronika
    BIOMEDICINES, 2022, 10 (09)
  • [43] Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease
    Witt, Leah J.
    Demchuk, Carley
    Curran, James J.
    Strek, Mary E.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2016, 36 : 46 - 52
  • [44] RITUXIMAB FOR THE TREATMENT OF CONNECTIVE TISSUE DISEASE-ASSOCIATED INTERSTITIAL LUNG DISEASE
    Chartrand, Sandra
    Swigris, Jeffrey J.
    Peykova, Lina
    Fischer, Aryeh
    SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2015, 32 (04) : 296 - 304
  • [45] Enrichment strategies for clinical trials targeting skin fibrosis and interstitial lung disease in systemic sclerosis
    Herrick, Ariane L.
    Denton, Christopher P.
    CURRENT OPINION IN RHEUMATOLOGY, 2023, 35 (06) : 349 - 355
  • [46] Pregnancy course in patients with interstitial lung diseases
    Novikova, Lubov
    Ilkovich, Yulia
    Dzadzua, Dali
    Korzina, Natalia
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [47] Progression of fibrosing interstitial lung disease
    Alyson W. Wong
    Christopher J. Ryerson
    Sabina A. Guler
    Respiratory Research, 21
  • [48] Interstitial lung disease associated with ALK inhibitors and risk factors: an updated comparative pharmacovigilance analysis
    Dong, Junli
    Li, Lulu
    Deng, Tiying
    Song, Haibin
    Zhang, Shaohui
    Zhong, Minyu
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [49] Second-line Chemotherapy for Patients with Small Cell Lung Cancer and Interstitial Lung Disease
    Fujimoto, Daichi
    Shimizu, Ryoko
    Kato, Ryoji
    Sato, Yuki
    Kogo, Mariko
    Ito, Jiro
    Teraoka, Shunsuke
    Otoshi, Takehiro
    Nagata, Kazuma
    Nakagawa, Atsushi
    Otsuka, Kojiro
    Katakami, Nobuyuki
    Tomii, Keisuke
    ANTICANCER RESEARCH, 2015, 35 (11) : 6261 - 6266
  • [50] Concordance between sequential transbronchial lung cryobiopsy and surgical lung biopsy in patients with diffuse interstitial lung disease
    Zaizen, Yoshiaki
    Kohashi, Yasuo
    Kuroda, Kishio
    Tabata, Kazuhiro
    Kitamura, Yuka
    Hebisawa, Akira
    Saito, Yuji
    Fukuoka, Junya
    DIAGNOSTIC PATHOLOGY, 2019, 14 (01)